News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016
Shire (SHPG)'s Retinopathy Treatment Fails to Meet Primary Endpoint in Phase II 6/30/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
Novartis AG (NVS) PKC412 (Midostaurin) Pivotal Data Published In The New England Journal of Medicine Show 60% Response Rate In Advanced Systemic Mastocytosis (SM) 6/30/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Adolescents With Sickle Cell Disease 6/30/2016
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016
Zytoprotec GmbH Completes Enrollment In Phase II Study With Novel Peritoneal Dialysis Fluid 6/30/2016
BioMarker Strategies Awarded Phase I/II Fast Track National Cancer Institute Grant To Develop Companion Diagnostic Test To Select Optimal Therapy For Patients With Non-Small Cell Lung Cancer 6/30/2016
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease 6/29/2016
BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results For BPX-01 In Patients With Acne-Causing Bacteria 6/29/2016
Aurinia (ISA.TO) Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN) 6/29/2016
New Kid Vidac Pharma Completes $9 Million Series A Financing; Advances Phase II VDA-1102 6/29/2016
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 2 Study In Female Patients With Colorectal Cancer Metastatic To The Liver 6/29/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD) 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Marinus Pharma (MRNS)'s Primary Endpoint Not Met in Ganaxolone Phase II 6/28/2016
Zynerba (ZYNE) Announces Positive Top Line Results From ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial And Initiation Of Phase 2 Study In Adult Epilepsy Patients With Refractory Focal Seizures 6/28/2016
Bristol-Myers Squibb (BMY)'s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation 6/28/2016
Immune Pharma Release: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 6/28/2016
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016
BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 6/28/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 2 Portion Of Clinical Trial Of GMI-1271 In Newly Diagnosed Acute Myeloid Leukemia 6/28/2016
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
Xencor Provides Updates On Lead Programs And Reviews Bispecific Oncology Partnership; Announces Expansion Of Bispecific Oncology Pipeline At Analyst Day 6/28/2016
Allergy Therapeutics Phase II Fails to Find Hay Fever Therapy Dose Range 6/27/2016
Akcea Therapeutics Announces Publication Of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides And Improved Insulin Sensitivity In Patients With High Triglycerides And Type 2 Diabetes 6/27/2016
Santalis Announces Positive Results From A Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation For The Treatment Of Mild-To-Moderate Plaque Psoriasis 6/27/2016
TWi Biotechnology Announces Last Patient Enrolled In Phase 2 Study Of AC-201CR For Gout Treatment 6/27/2016
Stealth Biotherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide For The Treatment Of Heart Failure 6/27/2016
Alnylam (ALNY) To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis 6/27/2016
Neurotrope Announces That A New Study Published In The Journal of Biological Chemistry Shows That Bryostatin, A PKC Epsilon Activator, Generates New Synapses Through Accumulation Of The Synaptic Anchoring Protein PSD-95 At Neuronal Membranes 6/23/2016
Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase II LARIAT Study In Pulmonary Arterial Hypertension 6/23/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson's Disease And Movement Disorders 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors 6/23/2016
Taiwan Liposome Company Completes Trial Enrollment For Arthritis Treatment 6/23/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson´s Disease And Movement Disorders 6/23/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Two Upstarts that Could Dislodge Gilead (GILD)'s Hold on the Hepatitis C Market 6/22/2016
AXON Neuroscience’s Pioneering Tau Vaccine Against Alzheimer's Started Phase II 6/22/2016
Frontier Biotechnologies Reports Primary Endpoint Met In Phase 2 Trial Of AB001 In Chronic Low Back Pain 6/22/2016
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn (CYDY)’s Phase IIb Monotherapy Extension Study Now Available 6/22/2016
Prima Biomed (PRR.AX) Announces First Safety, Pharmacokinetics And Immuno-Monitoring Data From Phase IIb Clinical Trial Of IMP321 6/22/2016
Ardelyx (ARDX) Reports Progress Of Development Programs 6/22/2016
ViaCyte To Present At ISSCR 2016 Annual Meeting 6/22/2016
Epizyme (EPZM) to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients 6/21/2016
Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen 6/21/2016
AiVita Biomedical Receives FDA Approval For Phase II Ovarian Cancer Treatment 6/21/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
ContraVir Doses First Patients In Head-To-Head Study Of CMX157 Vs. Viread For Treating Hepatitis B 6/21/2016
TapImmune (TPIV) Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200 6/21/2016
Trek Therapeutics Initiates Phase 2a Study Of Faldaprevir And TD-6450, With And Without Ribavirin, In Patients With HCV GT 1b. 6/21/2016
Oramed (ORMP) Announces $6.5 Million Milestone Payment From HTIT 6/21/2016
Global Blood Therapeutics (GBT) Announces Pricing Of Public Offering Of Common Stock 6/21/2016
Asterias Biotherapeutics Announces Oral Presentation And Participation In Panel Discussion At The ISSCR 14th Annual Meeting 6/21/2016
Results Of Phase II Study Of Merck & Co. (MRK)’s Investigational Beta-Lactamase Inhibitor Relebactam In Combination With Imipenem/Cilastatin Presented At ASM Microbe 6/20/2016
TiGenix Announces Six-Month Phase I/II Results Of Allocsc-01 In Acute Myocardial Infarction 6/20/2016
Seres Therapeutics Presents New Data At ASM Microbe 2016, Including Characterization Of SER-262, The Rationally-Designed, Fermented Microbiome Therapeutic Candidate For Primary Clostridium Difficile Infection 6/20/2016
Epizyme (EPZM) Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At American Society of Hematology Lymphoma Biology Meeting 6/20/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Idiopathic Pulmonary Fibrosis 6/20/2016
Takeda (TKPYY) Initiates World’s First Norovirus Vaccine Field Trial 6/20/2016
Hutchison China MediTech (Chi-Med) Release: Savolitinib Global Phase II Trial Initiated In EGFR Mutant Non-Small Cell Lung Cancer 6/20/2016
Medgenics, Inc. Announces Enrollment Of First Patient In Phase 2/3 Clinical Trial Of NFC-1 In Adolescents With mGluR Mutation Positive ADHD 6/17/2016
Tobira’s Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology 6/17/2016
MorphoSys AG Reports Publication Of Clinical Case Report Of A Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission Of Currently 26 Months Under MOR208 Treatment 6/17/2016
CytoDyn (CYDY)n’s PRO 140 Phase IIb HIV Monotherapy Trial Findings To Be Presented At ASM Microbe 2016 Conference On June 20 6/17/2016
Arsanis Presents Data At ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia Coli And Klebsiella Pneumoniae Using Monoclonal Antibody Technology 6/17/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
OncoSec Medical Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference 6/16/2016
NLS Pharma Release: FDA Accepts IND For Phase II Study Of Mazindol In Adults With ADHD 6/16/2016
Shire (SHPG) Nabs Breakthrough Tags for Drug to Treat Rare Gastrointestinal Conditions 6/15/2016
Noveome Initiates Phase II Clinical Trial Of ST266 To Treat Patients With Periodontitis 6/15/2016
Flex Pharma (FLKS) Initiates Phase II Efficacy Study In Multiple Sclerosis 6/15/2016
Hansa Medical: Successful Desensitization With IdeS In All Recruited Patients In Ongoing U.S. Phase II Study 6/15/2016
Immune Pharma Expands Its Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid To Six Academic Institutions In The United States 6/15/2016
European Society of Cardiology Selects CardioCell's Heart Failure (HF) Study Results For ESC Congress 2016 Late-Breaking Science Session 6/15/2016
Soterix Medical Awarded $2.5 Million NIH Grant To Run Phase-II Efficacy Trial To Treat Aphasia After Stroke With HD-Tdcs 6/15/2016
Amoy Diagnostics Co. LTD. ROS1 Diagnostics Test Contributed To A Phase 2 Clinical Study Of Crizotinib In Lung Cancer 6/15/2016
Infinity Pharma (INFI) to Eliminate 46 Researchers After Lymphoma Drug Disappoints in Study 6/14/2016
vTv Therapeutics Presents Positive Results From A Pilot Study Of Its Glucokinase Activator At American Diabetes Association 76th Scientific Sessions 6/14/2016
Eiger Biopharma Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia 6/14/2016
Janssen R&D Release: Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements In Adults With Type 1 Diabetes 6/14/2016
The Medicines Company (MDCO) Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700 6/14/2016
City of Hope Release: Autologous Stem Cell Transplantation Offers Safe And Effective, And Potentially Curative, Option For Patients With HIV-Associated Lymphoma 6/14/2016
Agios (AGIO)' Anemia Drug Data Hits Mark in Mid-Stage Study 6/13/2016
Zafgen (ZFGN) Presents New Data From The Phase IIb Clinical Trial Evaluating Beloranib In Severe Obesity Complicated By Type 2 Diabetes At The American Diabetes Association's 76th Scientific Sessions 6/13/2016
Melior Pharmaceuticals Announces Positive Phase IIA Results In Type 2 Diabetes Study 6/13/2016
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide And Dexamethasone For The Treatment Of Multiple Myeloma 6/13/2016
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial 6/13/2016
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial 6/13/2016
Aimmune (AIMT) Announces Phase II Extended Maintenance Data Supporting Safety And Tolerability Profile Of AR101 For Peanut Allergy 6/13/2016
Janssen R&D Release: New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management 6/13/2016
BioSpecifics Technologies Corporation (BSTC) Announces Positive Top-Line Results From Phase 2 Trial Of CCH For Treatment Of Human Lipoma 6/13/2016
Galena Biopharma  (GALE) Receives Two Orphan Drug Designations For GALE-301 And GALE-301/GALE-302 6/13/2016
Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due To The Targeting Of MCL-1 6/13/2016
Poxel Presents New Data On Imeglimin’s Dual Mechanism Of Action At The American Diabetes Association’s 76th Scientific Sessions 6/13/2016
Global Blood Therapeutics (GBT) Stock Surges on Promising Sickle Cell Drug Results 6/10/2016
Sophiris Bio (SPHS) Reports Successful Results From Completed Phase 2a Study Of Topsalysin In Localized Prostate Cancer 6/10/2016
Data In The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase In Overall Survival In Patients With Advanced Soft Tissue Sarcoma, As Reported By Eli Lilly (LLY) And Memorial Sloan-Kettering Cancer Center Researchers 6/10/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association 6/10/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association 6/10/2016
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity Of Its Lead Drug Candidates At 21st Congress Of The European Hematology Association 6/10/2016
New Data On Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) Indicate Benefit In Heavily Pre-Treated Classical Hodgkin Lymphoma Patients In Phase II, Single-Arm Pivotal Trial 6/10/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
NuSirt Presenting New Research At American Diabetes Association’s 76th Annual Scientific Sessions 6/10/2016
AVANIR (AVNR) To Present Data On ONZETRA Xsail At American Headache Society (AHS) 2016 Annual Scientific Meeting 6/10/2016
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016
Cidara Therapeutics (CDTX) Doses First Patient In Phase II Trial Of CD101 Topical To Treat Vulvovaginal Candidiasis 6/9/2016
Galmed Pharmaceuticals Adds China Arm To Phase IIb Trial Of Liver Disease Drug 6/9/2016
Biogen (BIIB) Loses $8 Billion in Market Value in One Day After Failed Trial 6/8/2016
Catabasis (CATB) Craters as Cholesterol Drug Flunks Mid-Stage Study 6/8/2016
Istituto Superiore di Sanita Release: Improving The Effect Of HIV Drugs By Use Of The Tat Vaccine 6/8/2016
Bone Therapeutics Demonstrates Superiority Of PREOB In Phase IIB Osteonecrosis Study Presented At EULAR 6/8/2016
Fibrocell (FCSC) Tumbles as Lead Product Did Not Meet Primary Endpoints in Phase II Study 6/8/2016
ProvectusAnnounces Publication Of Article On PV-10 For In-Transit Melanoma In Journal Of Surgical Oncology 6/8/2016
ASCO2016: What's Next For Cancer-Killing T-Cells After Strong ASCO Showings 6/8/2016
Millendo Therapeutics Announces Initiation Of Phase II Clinical Trial Of ATR-101 In Patients With Congenital Adrenal Hyperplasia 6/8/2016
Amarantus Announces cGMP Manufacturing Readiness For Its Engineered Skin Substitute (ESS) Program At Lonza Walkersville 6/8/2016
Biogen (BIIB)'s Stock Falls as MS Drug Fails to Meet Endpoints in Mid-Stage Study 6/7/2016
Down's Syndrome 'Can Be Treated With Green Tea,' Centre for Genomic Regulation Study 6/7/2016
ASCO2016: Gem Pharmaceuticals Presents Promising Phase 2 Data For GPX-150 In Sarcoma Patients At The 2016 ASCO Annual Meeting 6/7/2016
Regulus (RGLS) Reports Positive Top-line Data 6/7/2016
Hemispherx (HEB): Dr. William M. Mitchell Publishes Article Titled, “Efficacy Of Rintatolimod In The Treatment Of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” In Expert Review Of Clinical Pharmacology 6/7/2016
Galmed Pharmaceuticals Expands Its Ongoing Phase IIb ARREST Study To China 6/7/2016
Aldeyra Therapeutics (ALDX) Announces Last Patient Dosed In Phase II Clinical Trial Of Topical Dermatologic NS2 In Patients With Sjögren-Larsson Syndrome 6/7/2016
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1143 In Ovarian Cancer 6/7/2016
NeuroVive (NVP) Announces CiPRICS Study Completes Enrollment 6/7/2016
Remedy Pharmaceuticals, Inc. Announces Contest To Name Its Subarachnoid Hemorrhage Clinical Trial 6/7/2016
TapImmune (TPIV) Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine 6/7/2016
Eli Lilly (LLY) Release: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology (EULAR 2016) 6/7/2016
Aimmune (AIMT)Announces Late-Breaker Presentation At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2016 6/7/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Genentech (RHHBY)'s TECENTRIQ Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer 6/6/2016
Stealth Biotherapeutics Reports Positive Results For Primary Mitochondrial Myopathy Trial 6/6/2016
New Study Led By John Theurer Cancer Center Researcher Demonstrates Potential Therapeutic Benefit Of TPI 287 With Bevacizumab In Treatment Of Aggressive Brain Cancer 6/6/2016
Halozyme (HALO) Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 6/6/2016
Novartis AG (NVS) Pivotal Data For Tafinlar + Mekinist Demonstrated A 63 Percent Overall Response Rate In Treating Rare Form Of Lung Cancer 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ProNAi Therapeutics, Inc. Reports Interim Data From Wolverine Phase 2 Trial Of PNT2258 In DLBCL 6/6/2016
Soligenix (SNGX) Announces Presentation Of Phase 2 Oral Mucositis Clinical Trial Results At The 2016 Multinational Association For Supportive Care In Cancer Conference 6/6/2016
ASCO2016: CytRx (CYTR) Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: GANYMED Pharmaceuticals AG's IMAB362 Extends Survival In Gastric Cancer 6/6/2016
Eli Lilly (LLY) Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 6/6/2016
ASCO2016: Immunomedics (IMMU) Breast Cancer Abstract Booted from Conference 6/6/2016
ASCO2016: Early-Phase Immuno-Oncology Studies Of Eli Lilly (LLY)'s ALIMTA (Pemetrexed) And CYRAMZA (Ramucirumab) With Merck & Co. (MRK)'s KEYTRUDA (Pembrolizumab) Show Encouraging Results In Non-Small Cell Lung Cancer 6/6/2016
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016
ASCO2016: DelMar Pharma Presents Phase I/II GBM Clinical Trial Data And Outlines Future Clinical Development Plans At ASCO 2016 Annual Meeting 6/6/2016
ASCO2016: MorphoSys AG Presents Updated Clinical Data For MOR202 In Multiple Myeloma And For MOR208 In Non-Hodgkin's Lymphoma At ASCO 2016 6/6/2016
ASCO2016: Merck & Co. (MRK) And Pfizer (PFE) Release: Pivotal Avelumab Study Shows Positive Results In Metastatic Merkel Cell Carcinoma 6/6/2016
ASCO2016: Merck & Co. (MRK)'s KEYTRUDA (Pembrolizumab) Shows Overall Response Rates Of 73 To 83 Percent, With Complete Response Rates Of 27 To 30 Percent, In Heavily Pre-Treated Patients With Chl, In Update To Study KN-087 6/6/2016
ASCO2016: New Data On Olmutinib (BI 1482694) Presented At ASCO 2016 Underscores Clinical Potential Of Boehringer Ingelheim’s Next Generation Lung Cancer Compound 6/6/2016
ASCO2016: Tyrogenex, Inc. Presents Data Informing Phase II And Supporting Potential Efficacy Of X-82 With Everolimus In Patients With Solid Tumors At The ASCO Annual Meeting 2016 6/6/2016
ASCO2016: Bristol-Myers Squibb (BMY) Release: First Presentation Of Phase II Checkmate -142 Study Evaluating Opdivo (Nivolumab) Alone Or In Combination With Yervoy (Ipilimumab) Demonstrates Encouraging Clinical Activity In MSI-High Metastatic Colorectal Cancer 6/6/2016
ASCO2016: Puma Biotech (PBYI) Presents Positive Phase II Data At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Merck & Co. (MRK) Release: New KEYTRUDA (Pembrolizumab) Data From KEYNOTE-010 And KEYNOTE-001 In Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Merck & Co. (MRK) Release: New Data Evaluating KEYTRUDA (Pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging From 48 To 71 Percent 6/6/2016
ASCO2016: Clovis Oncology (CLVS) Presents Data From Phase II Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: NuCana Acelarin Achieves High Clinical Activity And Durable Disease Control In Patients With Recurrent Ovarian Cancer 6/6/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase II Portion Of GMI-1271 Clinical Trial In Relapsed/Refractory Acute Myeloid Leukemia 6/6/2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Idiopathic Pulmonary Fibrosis 6/6/2016
Corcept Therapeutics Inc. (CORT) Provides Update Of Progress In Cortisol Modulation Oncology Program 6/6/2016
Mirati Therapeutics  (MRTX) Provides Progress Update On Current Clinical Trials 6/6/2016
Axovant (AXON) Announces 2015 Fiscal Year-End Financial Results And Corporate Updates 6/6/2016
ASCO2016: CellAct Pharma Phase II CAP7.1 Population Pharmacokinetic Data Supports Efficacy Results In Biliary Tract Cancers 6/3/2016
SanBio, Inc. Publishes Interim 12-Month Phase 1/2a Clinical Trial Results In The Peer-Reviewed Medical Journal, Stroke 6/3/2016
Novavax (NVAX) Announces New Seasonal Combination Respiratory Vaccine Program 6/3/2016
Novartis Pharmaceuticals Corporation (NVS) Announces US Collaboration To Co-Promote Lenvima In Combination With Everolimus For Advanced Renal Cell Carcinoma (RCC) 6/3/2016
Eisai Inc. (ESALF.PK) Enters Into A Collaboration Agreement To Co-Promote LENVIMA (Lenvatinib) In Combination With Everolimus In The U.S. 6/3/2016
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City 6/3/2016
Peregrine (PPHM) Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC (AZN)’s Durvalumab 6/2/2016
Addex Therapeutics (ADXN.SW) Dipraglurant Positive Phase 2 Data In PD-LID Published In Leading Peer Reviewed Journal Of The Movement Disorder Society 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
The Medicines Company (MDCO) Completes Patient Enrollment For ORION-1 Study Of PCSK9si 6/2/2016
HedgePath Pharmaceuticals Release: FDA Grants Orphan Drug Designation to SUBA-Itraconazole For Treatment Of Patients With BCCNS 6/2/2016
Therabron Receives From FDA Rare Pediatric Disease Designation For Lead Phase 2 Program In Preterm Infants 6/2/2016
Trevi Therapeutics Announces Completion Of Enrollment In Phase II/III Study Of Nalbuphine ER In Prurigo Nodularis 6/2/2016
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 6/2/2016
Isofol Medical AB Has Successfully Advanced To The Next Dose Level Of Modufolin In A Phase I/II Clinical Trial In Colorectal Cancer 6/2/2016
Global Blood Therapeutics (GBT) To Host Investor Event On Friday, June 10 To Review GBT440 Data In Sickle Cell Disease Being Presented At The European Hematology Association's 21st Congress 6/2/2016
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication Of Myrcludex B Clinical Results In Journal Of Hepatology 6/1/2016
ASCO2016: Kite Pharma (KITE) To Highlight Key Data From Engineered CAR T Cell Therapy Pipeline At The 2016 ASCO Annual Meeting 6/1/2016
ContraVir Initiates Head-To-Head Phase 2a Clinical Study Of CMX157 Vs. Viread For Treating Hepatitis B 6/1/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
Galmed Pharmaceuticals Randomizes 120th Patient In The ARREST Trial 6/1/2016
Stealth Biotherapeutics Initiates Phase 2 Study Of Elamipretide In Leber's Hereditary Optic Neuropathy 6/1/2016
GeNeuro Announces First Patients Treated In Phase 2b Study For Multiple Sclerosis 6/1/2016
Regulus (RGLS) Expands Clinical Trial Collaboration With GlaxoSmithKline (GSK) 6/1/2016
ProNAi Therapeutics, Inc. Appoints Dr. Christian Hassig As Senior Vice President Of Research 6/1/2016
ASCO2016: City of Hope Presents New Cancer Research At American Society Of Clinical Oncology Meeting 6/1/2016
Resolution Bioscience's ctDx Blood-Based NGS Platform Used For Plasma Genotyping And Longitudinal Monitoring Of ALK Fusion Positive Patients In Clinical Trial 6/1/2016
Regeneron (REGN) Presents Positive Interim Data From Phase 2 Proof-Of-Concept Study Of Evinacumab In Patients With Homozygous Familial Hypercholesterolemia 5/31/2016
Antibe Therapeutics (ATE.V) Presenting Update On ATB-346 At International Hydrogen Sulfide Conference 5/31/2016
Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology 5/31/2016
GeNeuro Announces First Patients Treated In Phase IIb Study For Multiple Sclerosis 5/31/2016
Ongoing Clinical Development Of ABX464: ABIVAX Launches ABX464-004 Study 5/31/2016
FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics (CDTX)’ Novel Antifungal Product Candidate 5/31/2016
Ariad (ARIA) Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer 5/31/2016
Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase II Clinical Trial 5/31/2016